OOIR: Observatory of International Research

Papers

(The median citation count of Liver International is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort	142
TIPS Superiority in Refractory Variceal Haemorrhage: Insights From the TIPSEMS ‐ VB	117
Response to Letter to the Editor: “Chronic Nanoplastic Exposure as a Novel Risk Amplifier for MASLD Progression”	96
Navigating portal hypertension: Unlocking safe passage to healthy pregnancy in EHPVO	95
Importance of gender differences in body composition for liver transplantation and the ‘Sarco‐Model’ study	93
Golexanolone improves fatigue, motor incoordination and gait and memory in rats with bile duct ligation	91
Cardiac Geometry in Cirrhosis: Translation to Public Health and Trial Design	90
Reply to “Probiotics for Hepatic Encephalopathy Prevention After TIPS : Still an Open Question”	84
Immunogenicity and safety of a third dose of anti‐SARS‐CoV‐2 BNT16b2 vaccine in liver transplant recipients	84
Benefits of Using cT1 for Risk Stratification in MASLD	74
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease	70
HBV cure—The light at the end of the tunnel?	69
Fatty liver disease at the basis of cardiac remodelling and increased heart rate: Insights from the UK Biobank	63
Inside Front Cover	60
Is ageing a problematic hurdle to the efficacy of first‐line atezolizumab plus bevacizumab in hepatocellular carcinoma?	56
Different methodologies of protein induced by vitamin K absence or antagonist II in patients without hepatocellular carcinoma	52
Changing epidemiological features of hepatocellular carcinoma: Taiwan's position	52
Letter to the Editor regarding “Long‐term exposure to air pollution and incident non‐alcoholic fatty liver disease and cirrhosis”	52
Interpreting elevated liver blood test results through a genetic lens: A genome‐wide association study	51
Bringing evidence to the MAFLD‐MASLD debate	50
Association of Liver Disease and Chronic Pruritus: A Case–Control Study	48
Liver Disease Complicating Familial Mediterranean Fever: A Study on 66 Patients Out of 533 Adult From the JIR Cohort	47
Clarifying Treatment Pathway Differences and Exposure Bias in the CHIEF Cohort Study	47
On Evaluating GPT ‐4 for CHB Treatment Recommendations: Reproducibility, Vignette Design and Promp	44
The Relationship Between TNF‐α Inhibitor Potency and HBV Reactivation in Patients With Rheumatic Disorders	43

Impact of socio‐economic environment on incidence of primary liver cancer in France between 2006 and 2016	42
Determinants of worse liver‐related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort	42
Assessing Treatment Heterogeneity in Predictive Models for HCC Retreatment Response	42
Reply to Reconsidering the Impacts of Steatotic Liver Disease on Adverse Pregnancy Outcomes	42
Evaluation of Pathogenic Variants Associated With Monogenic Disorders of Dyslipidemia in Patients With Well Characterised MASLD	41
High disease burden and healthcare resource usage in patients with acute porphyria—A population‐based analysis	40
Integrating PNPLA3 into clinical risk prediction	40
Epidemiology and Risk Determinants of Drug‐Induced Liver Injury: Current Knowledge and Future Research Needs	40
Hospitalisations With Cryoglobulin‐Related Diseases in Spain Over 25 Years	39
Increased platelet ratio in patients with decompensated cirrhosis indicates a higher risk of portal vein thrombosis	39
Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct‐acting antivirals	39
Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in Young Children With Chronic HCV Infection	38
Hepatocytic ballooning in non‐alcoholic steatohepatitis: Dilemmas and future directions	37
Primary Biliary Cholangitis Increases Mortality Irrespective of Presence or Absence of Cirrhosis	37
Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC	37
RETRACTION : Interferons α, β, γ Each Inhibit Hepatitis C Virus Replication at the Level of Inte	36
The integrated stress response‐related expression of CHOP due to mitochondrial toxicity is a warning sign for DILI	35
Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT‐FOXO3 signalling pathway	35
Low‐Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma	35
Correction to ‘Development and Validation of an Image Biomarker to Identify Metabolic Dysfunction Associated Steatohepatitis: MR ‐	34
Reply: Herbal‐Induced Liver Injury Identification and Prevention	34
Assessment of PBC Pruritus From the ITCH ‐E Study: Quality of Life, Productivity, and Treatment Ex	33
Loss of Mtarc1 Protects Against Steatotic Liver Disease in Mice	33
Perilipin 5 protects the mitochondrial oxidative functions and improves the alcoholic liver injury in mice	33
Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy	33
Prognostic Role of Endoscopic Ultrasound Guided Direct Portal Pressure Gradient Measurement in Porto‐Sinusoidal Vascular Disorder	32
Time since liver transplant and immunosuppression withdrawal outcomes: Systematic review and individual patient data meta‐analysis	32
Five‐year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study	32
Methylprednisolone‐Induced Liver Injury: Insights From FAERS Analysis and Comparison With DILIN Fi	32
Causal effect of lower birthweight on non‐alcoholic fatty liver disease and mediating roles of insulin resistance and metabolites	31
Prevalence of metabolic dysfunction‐associated steatotic liver disease in the Middle East and North Africa	31
A Markov Model Unveiling the Impact of Resmetirom on the Natural History of MASLD Patients: A Sistematic Review and Meta‐Analysis	31
Helicobacter pylori‐Associated Surrogate Markers of Intestinal Permeability, Bacterial Translocation and Gut Barrier Damage in Liver Cirrhosis	31
Letter to the editor regarding “Exploring the landscape of steatotic liver disease in the general US population”	30
Response to: Impact of GLP ‐ 1RA on Adverse Liver Outcomes Among Patients With Alcohol‐Associated	29
Enhancing the Understanding of Obesity and Liver Health: Addressing Lifestyle, Socio‐economic and Ethnic Disparities	29
Increasing Prevalence of Steatotic Liver Disease in a Japanese Health Checkup Population, 2004–2022	29
¹⁶⁶ Ho‐RadioEmbolizaTiOn Using personalized prediCtive	29
Liver transplantation for autoimmune hepatitis: Pre‐transplant does not predict the early post‐transplant outcome	29
Outcomes and management in paediatric autoimmune hepatitis presenting as acute liver failure: Individual patient data meta‐analysis	28
Myeloid Glutamine Synthetase Protects Against Acute Liver Injury in Mice Independent of Its Enzyme Activity	28
Unravelling the Complex Role of Glycine‐Conjugated Bile Acids and Gut‐Liver Axis in Progressive Alcohol‐Related Liver Disease	28
HERACLIS_BLV_D: Increasing Response Rates During 2‐Year Bulevirtide Real‐Life Therapy in Chronic Hepatitis D	28
Research gaps and opportunities in autoimmune hepatitis—Results of the international autoimmune hepatitis group research workshop 2022	27
	27
NSBBs, EBL or Combined Therapy for High‐Risk Varices: Systematic Review and Meta‐Analysis	27
GDF ‐15 in Cirrhosis: Signal, Guide or Both?—Authors' Reply	27
Gastrointestinal cancers in lean individuals with non‐alcoholic fatty liver disease: A systematic review and meta‐analysis	26
Issue Information	26
Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study	26

Medical Management of Polycystic Liver Disease: A Position Statement From the European Reference Network on Hepatological Diseases	26
Role of Gut‐Derived Endotoxins in Porto‐Sinusoidal Vascular Disorder: Comparison Between patients with and without portal hypertension	26
Axon guidance molecules in liver pathology: Journeys on a damaged passport	26
Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child–Pugh Class B	26
Patients hospitalized with alcohol‐related liver disease and prior bariatric surgery are more prone to develop acute‐on‐chronic liver failure	26
Physician Perspectives on Hepatitis C Treatment During Pregnancy: A Multinational Multispecialty Survey	26
Autoimmune hepatitis (AIH) following coronavirus (COVID‐19) vaccine—No longer exclusive to mRNA vaccine?	25
Case‐based discussion of the acute hepatic porphyrias: Updates on pathogenesis, diagnosis and management	25
Appraisal of AI ‐Based Fibrosis Quantification in MASH	25
Response to letter from Skouloudi et al	25
Bulevirtide for patients with compensated chronic hepatitis delta: A review	25
Red meat intake, faecal microbiome, serum trimethylamine N‐oxide and hepatic steatosis among Chinese adults	24
Health‐related quality of life in patients with primary sclerosing cholangitis: A longitudinal population‐based cohort study	24
Extracellular vesicles in fatty liver disease and steatohepatitis: Role as biomarkers and therapeutic targets	24
Adding 100 Hz Spleen Stiffness Measurement to the Baveno VII Model Improves Decompensation Risk Pr	24
Characterization of lymphocyte‐rich hepatocellular carcinoma and the prognostic role of tertiary lymphoid structures	24
Liver GPBAR1 Associates With Immune Dysfunction in Primary Sclerosing Cholangitis and Its Activation Attenuates Cholestasis in Abcb4−/− Mice	23
Hepatic cell junctions: Pulling a double‐duty	23
Characteristics and Clinical Outcomes in Patients With Cirrhosis due to MASLD in Sweden	23
Multiple arterial‐phase MRI with gadoxetic acid improves diagnosis of hepatocellular carcinoma ≤3.0 cm	23
Microvesicle Tissue Factor Procoagulant Activity Is Elevated and Correlated With Disease Severity in Patients With Cirrhosis	23
HLA matching between donors and recipients improves clinical liver transplant graft survival	23
Global treatment rate and barriers to direct‐acting antiviral therapy: A systematic review and meta‐analysis of 146 studies and 1 760 352 hepatitis C virus patients	23
Gender differences of authors of major Hepatology society guidelines during the past 15 years	23
Inhibition of MALT1 Protease Attenuates Hepatic Sinusoidal Obstruction Syndrome by Modulating NRF2	22
Prevalence and Impact of Steatotic Liver Disease in Autoimmune Liver Diseases: A Systematic Review and Meta‐Analysis	22
Sodium–glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use	22
HLA ‐B44 Alleles and HLA‐DQA103:01 as Genetic Risk Factors for Drug‐Induced Liver Injury due to Fluoroquinolones	22
Hepatitis D Virus Infection: Pathophysiology, Epidemiology and Treatment. Report From the Third Delta Cure Meeting 2024	22
Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis	22
Spleen Stiffness Measured by 100‐Hz Probe Predicts Decompensation in Patients With Compensated Advanced Chronic Liver Disease	22
Issue Information	21
Author's reply: Plasma corticosteroid‐binding globulin levels in cirrhosis	21
Trends in prevalence of probable fibrotic non‐alcoholic steatohepatitis in the United States, 1999–2016	21
Response to Letter to the Editor: ‘Nanoplastics and MASLD : Unveiling Interorgan Crosstalk and Environmental Modulators’	21
Nonalcoholic fatty liver disease without overlapping metabolic‐associated fatty liver disease and the risk of incident type 2 diabetes	21
Predictors of mid‐term survival after liver transplantation in patients with NAFLD cirrhosis	21
Issue Information	21
Extrahepatic autoimmune diseases do not increase the mortality of autoimmune hepatitis	21
Third dose of mRNA COVID‐19 vaccine and response: Correspondence	21
Issue Information	21
Impairment of Regenerative and Metabolic Pathways in Intestinal Organoids From Patients With MASLD‐Cirrhosis	20
Featured Cover	20
Hepatic triglyceride content is intricately associated with numerous metabolites and biochemical pathways	20
Driving HCV Elimination Through Dedicated Hospital‐Based Teams and Pathways: A Retrospective and Prospective Study	20
Digital Histopathology and AI : A New Era of Liver Fibrosis Quantification	20
MRI ‐Based Score to Predict Retreatment Response for Viable Hepatocellular Carcinomas After Transarterial Chemoembolization	20
Response to Letter to the Editor: “Advancing TMPRSS6‐Targeted Therapy for MASLD: Mechanistic and Translational Perspectives”	20
Determining reinfection rates by hepatitis C testing interval among key populations: A systematic review and meta‐analysis	20
Enhanced muscle function in cause‐specific mortality among patients with NAFLD‐related sarcopenia	20
How best to combine liver transplantation and bariatric surgery?—Results from a global, web‐based survey	20
The changing epidemiology of liver diseases in Asia	20
Apolipoprotein A‐1 protected hepatic ischaemia–reperfusion injury through suppressing macrophage pyroptosis via TLR4–NF‐κB pathway	20
Global trends and the impact of chronic hepatitis B and C on disability‐adjusted life years	20
Bcl‐x_L as prognostic marker and potential therapeutic target in cholangiocarcinoma	20
Letter to the Editor: Interpreting the Clinical Applicability of SGLT ‐2 Inhibitors in MASH ‐Relat	20
Unmet needs in autoimmune hepatitis: Results of the prospective multicentre European Reference Network Registry (R‐LIVER)	20
Prognostic Implications of Cardiac Geometry in Cirrhosis: Findings From a Large Cohort	20
NAFLD and NASH are obesity‐independent risk factors in COVID ‐19: M	20
Issue Information	19
Response to Letter to ‘Serum CRP in Durvalumab–Tremelimumab‐Treated HCC : Expanding the Inflammato	19
Correction to ‘Chronic Nanoplastic Exposure Promotes the Development and Progression of Metabolic Dysfunction‐Associated Steatotic Liver Disease’	19
Practical recommendations for biochemical and genetic diagnosis of the porphyrias	19
An ultrasound multiparametric method to quantify liver fat using magnetic resonance as standard reference	19
Issue Information	19
Reply to the letter “Anti‐HBc level predicting virological relapse after stopping nucleos(t)ide analogue in chronic hepatitis B”	19
The Global Burden of Cirrhosis and Other Chronic Liver Diseases in 2021	19
Alcohol‐related liver disease phenotype impacts survival after an acute variceal bleeding episode	19
Regulation of the macrophage‐hepatic stellate cell interaction by targeting macrophage peroxisome proliferator‐activated receptor gamma to prevent non‐alcoholic steatohepatitis progression in mice	19
Quality Measures to Enhance the Management and Treatment of Primary Biliary Cholangitis: A Delphi Consensus Study	19
Issue Information	19
Bacterial Infections in Severe Alcohol‐Associated Hepatitis: Methodological Considerations	19
Immune checkpoint inhibitors in malignancies after liver transplantation: Better safe or sorry?	19
Comparison of primary liver cancer mortality estimates from World Health Organization, global burden disease and global cancer observatory	19
Response to: Passive Stent Expansion as a Confounder in Under‐Dilated TIPS Outcomes	19
Impact of PNPLA3 I148M on Drug‐Induced Hepatocellular Liver Injury: A Systematic Review and Meta‐Analysis	18
	18
Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook	18
Ketogenic Diet and Hepatic Ischaemia–Reperfusion Injury: Aggravation or Mitigation?	18
	18

Updated Liver Blood Test Reference Limits: Excellence in Methodology, Questions in Clinical Applicability	18
Locoregional Anti‐ GPC3 CAR ‐T for HCC : Strengths and Optimisation Directions	18
Refining the Safety Perspective of Bulevirtide in Chronic Hepatitis Delta Management	18
Response Letter to: Expanding Perspectives on FIB ‐4 as a Predictor of Hepatic and Extrahepatic Malignancy Risk	18
Response to Letter to ‘Serum CRP in Durvalumab‐Tremelimumab‐Treated HCC : Expanding the Inflammato	18
A Novel BAFF / APRIL Dual Inhibitor in Treating Refractory Autoimmune Hepatitis	18
Quality‐of‐life scores improve after 96 weeks of PEG‐IFNa‐2a treatment of hepatitis D: An analysis of the HIDIT‐II trial	18
Acute Transient Aminotransferase Elevation is Common With Intrathecal Methotrexate, but Liver Injury is Infrequent	18
SIRT5 Facilitates Liver Steatosis Progression via Promoting SDH Desuccinylation During High‐Fat Diet Feeding	18
Elevated Serum Bile Acids Predict Poor Liver Outcomes in Children With Alagille Syndrome: Results From the GALA Study Group	17
French guidelines on TIPS: Indications and modalities	17
Escherichia coli‐derived outer‐membrane vesicles induce immune activation and progression of cirrhosis in mice and humans	17
Altered ethanol metabolism and increased oxidative stress enhance alcohol‐associated liver injury in farnesoid X receptor‐deficient mice	17
Association of thyroid function with non‐alcoholic fatty liver disease in recent‐onset diabetes	17
Cost of Metabolic Dysfunction‐Associated Steatotic Liver Disease Screening Among All People Living With Diabetes in Six Countries	17
Determinants of HBsAg Loss After Nucleos(t)ide Discontinuation in a Prospective Cohort of HBeAg ‐N	17
Identification of Distinguishing Features of Drug‐Induced Liver Injury and Liver Injury Associated With Sepsis	17
Fifteen Years of PNPLA3 : Transforming Hepatology Through Human Genetics	17
MASLD and MASH Risk: Does Losing Obesity Reverse the Metabolic Footprint	17
Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis	17
Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals	17
Oxidised Apolipoprotein Peptidome Characterises Metabolic Dysfunction‐Associated Steatotic Liver Disease	17
Impact of GLP ‐ 1RA on the Risk of Adverse Liver Outcomes Among Patients With Alcohol‐Associated L	17
Pilot hepatitis C micro‐elimination strategy in Pakistani migrants in Catalonia through a community intervention	17
Prognostication of Liver Disease Patients via the WFUMB ‘Rule‐of‐4’ Algorithm Using SSI ‐	17
Outcome of Liver Retransplantation in Patients With Primary Sclerosing Cholangitis	17
Follow‐up post‐HCV virological response to DAA in advanced chronic liver disease	17
Treatment patterns for hepatocellular carcinoma in patients with Child–Pugh class B and their impact on survival: A Korean nationwide registry study	17
	16
Histological characterization of liver involvement in systemic mastocytosis	16
Overcoming the challenges of eliminating viral hepatitis in low‐ and middle‐income countries	16
Response to: Letter to the Editor “Child‐Turcotte‐Pugh score as a model for organ allocation in liver transplantation, perhaps old is still gold”	16
	16
Carvedilol as the new non‐selective beta‐blocker of choice in patients with cirrhosis and portal hypertension	16
FBXO31 sensitizes cancer stem cells‐like cells to cisplatin by promoting ferroptosis and facilitating proteasomal degradation of GPX4 in cholangiocarcinoma	16
Expanding the donor pool: Kidney transplantation from serum HBV DNA or HBeAg‐positive donors to HBsAg‐negative recipients	16
CD44 in Group 1 Innate Lymphoid Cells Impacts the Development and Progression of Steatohepatitis	16
Management of alcoholic hepatitis: A clinical perspective	16
The prognostic role of tumour progression and liver function at progression under immunotherapy for hepatocellular carcinoma	16
PRO‐C3, liver fibrosis and CKD: The plot thickens	16
Issue Information	16
Front Cover	16
Protective role of cGAS in NASH is related to the maintenance of intestinal homeostasis	16
From Theory to Practice: Which Biomarkers Are Ready for Predicting Response in Advanced HCC ?	16
Response to: “The Role of Platelets in MASLD : From Mechanisms to Clinical Implications”	16
An Explainable Machine Learning Model for Predicting Short‐Term Haemodynamic Changes Post‐ TIPS With Prognostic Implications	16
Autophagy in liver regeneration: Unravelling the endothelial cell's role and therapeutic prospects	16
Sweating it out: How physical activity can combat high genetic risk for nonalcoholic fatty liver disease	16
Response Letter to: Zebrafish: An emerging and expedient model for liver studies?	16
Recipient‐Donor Sex Constellation in Liver Transplantation for Hepatocellular Carcinoma: An ELTR Study — Author Reply	16
Issue Information	16
Future anti‐HDV treatment strategies, including those aimed at HBV functional cure	16
Issue Information	16
Correction to ‘Network Meta‐Analysis of Adjuvant Chemotherapy in Biliary Tract Cancers: Setting the Scene for New Randomized Evidence’	15
Clinical Impact and Therapeutic Management of Diabetes Mellitus in Patients With Decompensated Cirrhosis	15
Characteristics and outcome of anti‐hepatitis D virus positive patients with hepatocellular carcinoma	15
From Creatinine Cut‐Offs to Bedside Precision: A Road‐Map for Safer Terlipressin in Early Hepatorenal Syndrome	15
Global burden of acute hepatitis E between 1990 and 2019 and projections until 2030	15
Impact of sarcopenia on postoperative outcomes after hepatectomy in older patients with intrahepatic cholangiocarcinoma: A multicentre cohort study	15
Deficient chaperone‐mediated autophagy in macrophage aggravates inflammation of nonalcoholic steatohepatitis by targeting Nup85	15
Redefining Obesity Improves the Identification of Advanced Fibrosis Among MAFLD / MASLD Patients	15
Interpreting the Clinical Significance of Spleen Stiffness in Baveno VII Risk Stratification	15
	15
Letter to the Editor: MASLD In Adults With Type 1 Versus Type 2 Diabetes Undergoing Vibration‐Controlled Transient Elastography	15
MASLD And MASH Risk: Does Losing Obesity Reverse the Metabolic Footprint?	15
Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis	15
Metallothionein Safeguards Hepatic Zn‐Fe Homeostasis and Restrains Yap‐Driven Hepatic Fe Overload to Protect Against Chronic Liver Fibrosis	15
Novel insights into metabolic‐associated steatotic liver disease preclinical models	15
Indole‐3‐Acetic Acid Attenuates Metabolic‐Associated Steatohepatitis via APC to Inhibit β‐Catenin/Wnt Pathway	15
scRNA ‐Seq Reveals Sustained Pro‐Inflammation by Innate Immune Activation in In Utero HBV‐ Exposed Neonates of High	15
Protective effects of statins on the incidence of NAFLD–related decompensated cirrhosis in T2DM	15
Evaluating the Long‐Term Benefits of Medications for Alcohol Use Disorder in Alcohol‐Associated Cirrhosis	15
PNPLA3 variation and kidney disease	15
Bile Acids as a Liver‐Muscle Axis Mediator: Moving From Association to Intervention	15
Free Testosterone Is Associated With Worse Survival in Patients With Advanced Chronic Liver Disease Awaiting Liver Transplantation	15
Acute alcohol‐associated hepatitis: Latest findings in non‐invasive biomarkers and treatment	15
Inhibition of IRE‐1α Alleviates Pyroptosis and Metabolic Dysfunction‐Associated Steatohepatitis by Suppressing Gasdermin D	15
A Novel Score for Predicting Long‐Term Outcomes in Recanalisation‐Treated Patients With Budd‐Chiari Syndrome: A Multicentre Study	15
Transjugular intrahepatic portosystemic shunt for portal hypertension: 30 years experience from China	14
The Challenge of Adherence in Wilson Disease: An Opportunity for Nurse‐Led Interventions	14
Methodological Considerations on Early Hemostatic Treatment for Spontaneous Rupture of HCC	14
Response Letter to: Association of thyroid function with nonalcoholic fatty liver disease in recent‐onset diabetes	14
NSBBs , EBL or Combined Therapy for High‐Risk Varices: A Systematic Review and Meta‐Analysis	14
Not So Quiet on the Viral Front: Low‐Level HBV Viraemia Undermines Immunotherapy in HCC	14
Emergency Department Opt‐Out Testing for Hepatitis B: A Two‐Year UK Multicentre Evaluation of Outcomes Across Seven Sites	14
Response to comments on ‘Changing landscape of alcohol‐associated liver disease in younger individuals, women and ethnic minorities’	14
The immuno‐therapeutic potential of miR‐2392 in patients with hepatocellular carcinoma	14
Hepatitis Delta: Ready for primetime?	14
Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate	14
Featured Cover	14
Mortality for Any Hepatic Cause in People With Diabetes Compared to the Non‐Diabetic Population. A 10‐Year‐Observational Study	14
Issue Information	14
The importance of prospective drug‐induced liver injury registries	14
Issue Cover	14
Competing Risk of Mortality May Obscure the True Impact of Smoking on HCC in ACLD	14